BEMORLAR HECH NARSADAN BEXABAR QOLDIRILADI: HER2- MUSBAT SUT BEZI SARATONIDA TRASTUZUMAB (GERTSEPTIN) YURAK-QON TOMIR XAVFI HAQIDAGI AXBOROT VA UNI BOSHQARISH — BEMORLAR TAJRIBASINI OʻRGANUVCHI SIFAT TADQIQOTI
Keywords:
Kalit soʻzlar: sut bezi saratoni; Gertseptin; sifat usuli; bemor tajribasi; yurak disfunksiyasi; kardiotoksiklik.Abstract
ANNOTATSIYA
Maqsad. HER2-musbat sut bezi saratoni boʻyicha birlamchi yoki metastatik
tashxis qoʻyilgan, Trastuzumab (Gertseptin) bilan davolanayotgan yoki avval
davolangan ayollarda ushbu davolanish natijasida yuzaga kelishi mumkin boʻlgan
yurak disfunksiyasi xavfi haqidagi bilim darajasi va kuzatuv tartibini oʻrganish.
Usul. Sifat intervyusi orqali 14 nafar ayoldan Trastuzumab terapiyasining yurakka
bogʻliq xavflari, yurak zararlanishi alomatlari haqidagi bilimi, shuningdek davolash
jarayonida va undan keyin yurak faoliyatini kuzatib borish tartibi haqida soʻralgan;
maʼlumotlar tematik tahlil usulida tahlil qilindi.
Natijalar. Tematik tahlil natijasida (a) davolanishdan oldingi yurak xavfi haqidagi
bilim va xabardorlik, (b) davolash jarayonida va undan keyin yurak faoliyati hamda
xavfini kuzatib borish, (v) davolash jarayonida yurak zararlanishi belgilari haqidagi
xabardorlikda nomuvofiqliklar aniqlandi.
Xulosa. Bemorlar Trastuzumabdan kelib chiqishi mumkin boʻlgan yurak
zararlanishi xavfi toʻgʻrisida yetarli darajada qoʻllab-quvvatlanmagan va maʼlumot
bilan taʼminlanmagan his qiladilar; bu tibbiy yordam sifatini yaxshilash zarurligini
koʻrsatadi.
References
ADABIYOTLAR ROʻYXATI
1. Risks and causes of breast cancer | Cancer Research UK. cancerresearchuk.org
2. Breast cancer facts | Breast Cancer Now. breastcancernow.org
3. Slamon DJ, Godolphin W, Jones LA et al (1989) Studies of the HER-2/neu proto-
oncogene in human breast and ovarian cancer. Science 244(4905):707–712
4. Romond EH, Perez EA, Bryant J et al (2005) Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer. N Engl J Med
353(16):1673–1684
5. Loibl S, Gianni L (2017) HER2-positive breast cancer. Lancet 389(10087):2415–
2429
6. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al (2005) Trastuzumab after
adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med
353(16):1659–1672
7. Giordano SH, Temin S, Kirshner JJ et al (2014) Systemic therapy for HER2-positive
breast cancer: ASCO guideline. J Clin Oncol 32(19):2078–2099
8. Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in HER2-
positive breast cancer. N Engl J Med 365(14):1273–1283
9. Denduluri N, Somerfield MR, Eisen A et al (2016) Selection of optimal adjuvant
chemotherapy regimens for HER2 breast cancers: ASCO/Cancer Care Ontario
guideline. J Clin Oncol 34:2416–2427
10. Jackson C, Finikarides L, Freeman ALJ (2022) The adverse effects of trastuzumab-
containing regimes: a systematic review and meta-analysis. PLoS ONE
17(12):e0275321
11. Long HD, Lin YE, Zhang JJ et al (2016) Risk of congestive heart failure with
adjuvant trastuzumab: a meta-analysis. Oncologist 21(5):547–554
12. Jerusalem G, Lancellotti P, Kim SB (2019) HER2+ breast cancer treatment and
cardiotoxicity: monitoring and management. Breast Cancer Res Treat 177:237–250
13. Dempsey N, Rosenthal A, Dabas N et al (2021) Trastuzumab-induced
cardiotoxicity: a review of clinical risk factors. Breast Cancer Res Treat 188:21–
36
14. Balduzzi S, Mantarro S, Guarneri V et al (2014) Trastuzumab-containing regimens
for metastatic breast cancer. Cochrane Database Syst Rev 12(6):CD006242
15. Carmichael A, Rea D, Sintler M (2013) Factors predicting trastuzumab-related
cardiotoxicity. Anticancer Res 33(4):1717–1720
16. Tarantini L, Cioffi G, Gori S et al (2012) Trastuzumab adjuvant chemotherapy and
cardiotoxicity in real-world women. J Card Fail 18(2):113–119
17. Product Monograph - Roche. assets.roche.com
18. Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res
Psychol 3(2):77–101
